Akoya Biosciences Unveils Strategic Product Roadmap, Powered by the New IO60 and Upcoming Neurobiology Panels
Akoya Biosciences has announced its strategic product roadmap, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. The announcement follows the successful launch of Human IO60 and Mouse FFPE IO panels in November 2024. The company plans to release PhenoCode Human and Mouse FFPE Neurobiology panels at the end of Q1 and Q2 2025 respectively.
The IO60 panel has received positive feedback from key opinion leaders for its ability to analyze immune landscapes and tumor-immune interactions. Strategic partnerships with CROs including Precision for Medicine, BostonGene, and Infinity Scope have enhanced IO60's market adoption.
The upcoming neurobiology panels will focus on neurodegenerative diseases, neuroinflammation, and vascular integrity research. Both panels are optimized for the PhenoCycler-Fusion platform, which the company describes as the fastest spatial proteomics discovery tool.
Akoya Biosciences ha annunciato la sua roadmap strategica per i prodotti, presentando nuovi pannelli di neurobiologia ultrahigh-plex per applicazioni umane e murine. L'annuncio arriva dopo il lancio di successo dei pannelli Human IO60 e Mouse FFPE IO nel novembre 2024. L'azienda prevede di rilasciare i Pannelli Neurobiologia FFPE PhenoCode per Umani e Topi rispettivamente alla fine del primo e del secondo trimestre del 2025.
Il pannello IO60 ha ricevuto feedback positivi da parte di leader di opinione chiave per la sua capacità di analizzare i paesaggi immunitari e le interazioni tumore-immuni. Le partnership strategiche con CRO come Precision for Medicine, BostonGene e Infinity Scope hanno migliorato l'adozione del mercato di IO60.
I prossimi pannelli di neurobiologia si focalizzeranno sulle malattie neurodegenerative, sulla neuroinfiammazione e sulla ricerca sull'integrità vascolare. Entrambi i pannelli sono ottimizzati per la piattaforma PhenoCycler-Fusion, che l'azienda descrive come il più veloce strumento di scoperta in proteomica spaziale.
Akoya Biosciences ha anunciado su hoja de ruta estratégica de productos, presentando nuevos paneles de neurobiología ultrahigh-plex para aplicaciones en humanos y ratones. El anuncio se produce tras el exitoso lanzamiento de los paneles Human IO60 y Mouse FFPE IO en noviembre de 2024. La compañía planea lanzar los Paneles Neurobiología FFPE PhenoCode para Humanos y Ratones a finales del primer y segundo trimestre de 2025, respectivamente.
El panel IO60 ha recibido comentarios positivos de líderes de opinión clave por su capacidad para analizar paisajes inmunitarios e interacciones tumorales-inmunitarias. Las asociaciones estratégicas con CROs, incluyendo Precision for Medicine, BostonGene e Infinity Scope, han mejorado la adopción en el mercado del IO60.
Los próximos paneles de neurobiología se centrará en enfermedades neurodegenerativas, neuroinflamación e investigación sobre la integridad vascular. Ambos paneles están optimizados para la plataforma PhenoCycler-Fusion, que la compañía describe como la herramienta de descubrimiento en proteómica espacial más rápida.
Akoya Biosciences는 인간 및 쥐 응용 프로그램을 위한 새로운 초고중첩 신경 생물학 패널을 특징으로 하는 전략적 제품 로드맵을 발표했습니다. 이 발표는 2024년 11월에 인간 IO60 및 쥐 FFPE IO 패널의 성공적인 출시 후에 이루어졌습니다. 회사는 2025년 1분기와 2분기 말에 각각 PhenoCode 인간 및 쥐 FFPE 신경 생물학 패널을 출시할 계획입니다.
IO60 패널은 면역 풍경 및 종양-면역 상호 작용을 분석하는 능력에 대해 주요 의견 리더들로부터 긍정적인 피드백을 받았습니다. Precision for Medicine, BostonGene 및 Infinity Scope를 포함한 CRO와의 전략적 파트너십이 IO60의 시장 수용을 촉진했습니다.
다가오는 신경 생물학 패널은 신경퇴행성 질환, 신경 염증 및 혈관 무결성 연구에 중점을 둘 것입니다. 두 패널 모두 회사가 가장 빠른 공간 프로테오믹스 발견 도구로 설명하는 PhenoCycler-Fusion 플랫폼에 최적화되어 있습니다.
Akoya Biosciences a annoncé sa feuille de route stratégique de produits, présentant de nouveaux panneaux de neurobiologie ultrahigh-plex pour des applications humaines et murines. L'annonce fait suite au lancement réussi des panneaux Human IO60 et Mouse FFPE IO en novembre 2024. La société prévoit de lancer les Panneaux Neurobiologie FFPE PhenoCode pour Humains et Souris à la fin du premier et du deuxième trimestre 2025 respectivement.
Le panneau IO60 a reçu des retours positifs de la part de leaders d'opinion clé pour sa capacité à analyser les paysages immunitaires et les interactions tumeur-immune. Des partenariats stratégiques avec des CRO, y compris Precision for Medicine, BostonGene et Infinity Scope, ont amélioré l'adoption du marché pour l'IO60.
Les prochains panneaux de neurobiologie se concentreront sur les maladies neurodégénératives, la neuroinflammation et la recherche sur l'intégrité vasculaire. Les deux panneaux sont optimisés pour la plateforme PhenoCycler-Fusion, que la société décrit comme l'outil de découverte en protéomique spatiale le plus rapide.
Akoya Biosciences hat seine strategische Produkt-Roadmap angekündigt, die neue ultrahochauflösende Neurobiologie-Panels für menschliche und Maus-Anwendungen umfasst. Die Ankündigung folgt auf den erfolgreichen Start der Human IO60 und Mouse FFPE IO-Panels im November 2024. Das Unternehmen plant, die PhenoCode Human und Mouse FFPE Neurobiologie-Panels am Ende des ersten und zweiten Quartals 2025 herauszubringen.
Das IO60-Panel hat von wichtigen Meinungsführern positive Rückmeldungen für seine Fähigkeit erhalten, Immunlandschaften und Tumor-Immun-Interaktionen zu analysieren. Strategische Partnerschaften mit CROs wie Precision for Medicine, BostonGene und Infinity Scope haben die Marktdurchdringung des IO60 verbessert.
Die kommenden Neurobiologie-Panels werden sich auf neurodegenerative Krankheiten, Neuroinflammation und Forschung zur vaskulären Integrität konzentrieren. Beide Panels sind für die PhenoCycler-Fusion-Plattform optimiert, die das Unternehmen als das schnellste Entdeckungswerkzeug für räumliche Proteomik beschreibt.
- Strategic expansion into neurobiology market segment
- Successful partnerships with major CROs driving IO60 panel adoption
- Integration with PhenoCycler-Fusion platform enabling faster analysis
- Operational Manufacturing Center of Excellence supporting product expansion
- None.
Insights
The strategic product expansion represents a significant move for Akoya Biosciences in the spatial proteomics market. The launch of neurobiology panels demonstrates three critical strategic advantages:
- Market Diversification: Expanding beyond oncology into neurobiology opens up new revenue streams in the growing neurodegenerative disease research market, estimated at several billion dollars
- Technical Moat: The successful deployment of high-plex panels (60+ targets) creates significant barriers to entry, as developing such complex panels requires substantial R&D investment and manufacturing expertise
- Strategic Partnerships: The adoption by major CROs like Precision for Medicine and BostonGene validates the technology and provides built-in distribution channels
The establishment of a Manufacturing Center of Excellence is particularly noteworthy as it addresses scalability concerns and supports rapid product development. This infrastructure investment positions Akoya to potentially capture a larger share of the spatial biology market, which is projected to grow significantly.
The endorsements from key opinion leaders at prestigious institutions (Cedars-Sinai, University of Tokyo) carry substantial weight in the research community and could accelerate adoption rates. The timing of the neurobiology panel launches (Q1 and Q2 2025) aligns well with research budget cycles, potentially driving near-term revenue growth.
The automation capabilities through PhenoCycler-Fusion platform integration provide a compelling efficiency advantage, addressing a critical pain point in research workflows. This could drive both instrument placements and recurring reagent revenue, establishing a stronger razor-razor blade business model.
The technical specifications of Akoya's expanded panel portfolio represent a significant leap in spatial proteomics capabilities. The key technical advantages include:
- Simultaneous analysis of 60+ targets provides unprecedented multiplexing capability, enabling complex pathway analysis in a single experiment
- Optimization for both fresh and FFPE samples increases utility across different research applications
- Full automation through PhenoCycler-Fusion integration addresses reproducibility challenges in spatial proteomics
The expansion into neurobiology is particularly well-timed given the increasing focus on spatial aspects of neurodegenerative diseases. The ability to analyze vascular integrity alongside neuroinflammation markers could provide important insights for drug development in conditions like Alzheimer's and Parkinson's disease.
The mouse panel optimization for preclinical studies creates a valuable translational research pipeline, potentially accelerating the drug development process by enabling better correlation between animal models and human disease states. This positions Akoya as a key player in both basic research and drug development workflows.
Rapid menu expansion with new high-plex human and mouse neurobiology panels joining the recently launched Human IO60 and Mouse FFPE IO Panels
The new offerings solidify leadership in spatial biology and broaden reach to new verticals
MARLBOROUGH, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Akoya Biosciences, a spatial proteomics leader, announced its reagent product roadmap today, featuring new ultrahigh-plex neurobiology panels for human and mouse applications. Building on the success of the Human IO60 and Mouse FFPE IO panels, which debuted at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2024, this roadmap represents the next step in the company’s mission to provide cutting-edge tools for advancing research across multiple market including oncology, inflammatory disease and neurobiology.
Transforming Spatial Proteomics with IO60
Since its launch, the PhenoCode™ Discovery IO60 panel has been celebrated by key opinion leaders (KOLs) and contract research organizations (CROs) for its ability to generate deep insights into immune landscapes and tumor-immune interactions. Early adopters have highlighted its transformative potential:
- Dr. Simon Knott, Assistant Professor at Cedars-Sinai, stated, “The IO60 Panel has the potential to reshape spatial proteomics, opening new possibilities for immune research.”
- Dr. Suzuki Yutaka, Professor at the University of Tokyo, added, “With the IO60 Panel, we’re uncovering patterns in immune responses that were previously inaccessible, positioning it as a game-changer for understanding tumor-immune interactions at a deeper level.”
- Strategic alliances with leading CROs—including Precision for Medicine, BostonGene, and Infinity Scope—have further propelled the adoption of IO60 by integrating it into their core service offerings, making advanced spatial proteomics accessible to all researchers.
Ultrahigh-Plex Neurobiology Panels: A Major Step Forward
Expanding on the success of IO60, the company is set to release PhenoCode Human and Mouse FFPE Neurobiology panels at the end of Q1 and Q2 2025 respectively. These panels will address the critical need for comprehensive spatial insights in neuroscience research, enabling advancements in understanding neurodegenerative diseases, disease modeling, and therapeutic development.
Key Features of the New Human and Mouse Neurobiology Panels:
- Human Neurobiology Panel: This high-plex spatial proteomics panel features an extensive set of biomarkers to study neurodegenerative diseases, neuroinflammation, vascular integrity, and key therapeutic targets, making it a vital tool for advancing neuroscience research.
- Mouse Neurobiology Panel: Specifically optimized for preclinical studies, this panel offers unparalleled biomarker depth to support disease modeling, neurodevelopmental research, and translational applications, bridging the gap between discovery and clinical insights.
- Seamless Integration with PhenoCycler®-Fusion: Fully automated and optimized for the PhenoCycler-Fusion platform, the fastest spatial proteomics discovery tool, enabling unprecedented speed and resolution in insight generation.
“The rapid expansion of our PhenoCycler-Fusion content menu is a by-product of the efficiency and robustness of our fully operational Manufacturing Center of Excellence,” said Brian McKelligon, CEO of Akoya Biosciences. “Our new ready-to-use high-plex panels in oncology and neurobiology enable us to capture a continuously expanding market segment and drive discoveries and breakthroughs from discovery to translational research.”
Forward-Looking Statements
This press release contains forward-looking statements that are based on management’s beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements concerning our expectations about the potential and capabilities of our products, our ability to achieve market acceptance, and drive adoption of, our products, our ability to expand relevant market segments, our projections regarding timing of our future product launches, and other statements regarding our business operations and future performance.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this press release represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.
About Akoya Biosciences
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The Company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. Akoya offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode™ Panels and PhenoCycler®, PhenoImager® Fusion and PhenoImager HT Instruments. To learn more about Akoya, visit www.akoyabio.com.
FAQ
When will Akoya Biosciences (AKYA) release its new Human Neurobiology Panel?
What are the key features of AKYA's new Mouse Neurobiology Panel?
Which CROs have partnered with Akoya Biosciences (AKYA) for the IO60 panel?
What applications does AKYA's Human Neurobiology Panel target?
When was AKYA's IO60 panel initially launched?
